流感疫苗引入伙伴关系(PIVI):通过公私合作支持中低收入国家流感疫苗项目发展
本文回顾了流感疫苗引入伙伴关系(PIVI)2013至2018年首个五年经验,该公私合作项目通过限时疫苗捐赠和技术支持帮助中低收入国家建立可持续的国家流感疫苗接种项目。项目与17国卫生部合作,其中8国获得捐赠疫苗和技术支持,2国已过渡到国家持续支持,6国正增加国家支持以期2023年全面过渡;另有9国获得技术支持以构建国家政策制定和/或项目评估的证据基础。PIVI增加了伙伴国的疫苗使用,早期国家已展示可持续性进展,表明疫苗与技术支持的模型可在中低收入国家奏效。
要点
- PIVI通过限时疫苗捐赠和技术支持帮助中低收入国家建立可持续流感疫苗项目。
- 2013至2018年与17国合作,8国获疫苗与技术支持,其中2国已过渡到国家持续支持。
- 早期国家展示可持续性进展,表明疫苗与技术支持的模型可在中低收入国家奏效。
核心结论
- PIVI增加了伙伴国的疫苗使用,早期国家已展示可持续性进展,表明疫苗与技术支持的模型可在中低收入国家奏效。
研究设计与样本
- 本文回顾PIVI首个五年(2013至2018年)经验,包括概念、国家可持续性进展和教训总结。
- PIVI与17国卫生部合作,其中8国获得捐赠疫苗和技术支持,9国获得技术支持以构建证据基础。
主要发现
- 8个获得捐赠疫苗和技术支持的国家中,2国已过渡到国家持续支持,6国正增加国家支持以期2023年全面过渡到本地疫苗项目支持。
- 9个额外国家获得技术支持以构建国家政策制定和/或项目评估的证据基础。
临床怎么用
- 中低收入国家可借助限时疫苗捐赠和技术支持建立并维持国家流感疫苗接种项目。
- 项目设计应包含向本地持续支持的过渡计划,并以证据基础建设支持国家政策制定和项目评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Influenza vaccination remains the most effective tool for reducing seasonal influenza disease burden. Few Low and Middle-Income Countries (LMICs) have robust, sustainable annual influenza national vaccination programs. The Partnership for Influenza Vaccine Introduction (PIVI) was developed as a public-private partnership to support LMICs to develop and sustain national vaccination programs through time-limited vaccine donations and technical support. We review the first 5 years of experience with PIVI, including the concept, country progress toward sustainability, and lesson learned. Between 2013 and 2018, PIVI worked with Ministries of Health in 17 countries. Eight countries have received donated vaccines and technical support; of these, two have transitioned to sustained national support of influenza vaccination and six are increasing national support of the vaccine programs towards full transition to local vaccine program support by 2023. Nine additional countries have received technical support for building the evidence base for national policy development and/or program evaluation. PIVI has resulted in increased use of vaccines in partner countries, and early countries have demonstrated progress towards sustainability, suggesting that a model of vaccine and technical support can work in LMICs. PIVI expects to add new country partners as current countries transition to self-reliance.
引用
- Bresee JS, Lafond KE, McCarron M, et al. The partnership for influenza vaccine introduction (PIVI): Supporting influenza vaccine program development in low and middle-income countries through public-private partnerships. Vaccine. 2019. PMID: 31288998. doi:10.1016/j.vaccine.2019.06.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。